Personalis NeXT Dx Test
Personalis has launchedthe NeXT Dx Test, a next-generation sequencing panel designed to help oncologists identify potential therapies and clinical trial options for cancer patients. The assay analyzes approximately 20,000 genes in both the tumor exome and transcriptome, and includes advanced analytics to provide a diagnostic report on genetic alterations in medically important cancer genes, as well as emerging immunotherapy-related biomarkers such as microsatellite instability status and tumor mutational burden.
Pillar Biosciences Onco/Reveal Solid Tumor Panel
Pillar Biosciences has launched the Pillar Onco/Reveal Solid Tumor Panel, a 47-gene enrichment assay for research use. The panel leverages Pillar's SLIMamp enrichment chemistry, which uses primers that are designed to form stem loops to suppress unwanted amplicons during PCR amplification, enabling multiplexed NGS library preparation in a single tube. The test was licensed from Columbia University and recently received approval from the New York State Department of Health.
Viracor Eurofins 'Viracor TRAC'
Viracor Eurofins has begun offering its Viracor TRAC donor-derived, cell-free DNA assay for diagnosing kidney transplant rejection. The noninvasive liquid biopsy test has similar characteristics to other donor-derived cfDNA assays on the market, Viracor Eurofins said. Two ongoing prospective and one retrospective clinical trials are underway to further develop clinical data to support use of the test. The current gold standard for diagnosing kidney transplant rejection and surveillance is organ biopsy, which is both expensive and can lead to multiple complications for the patient, the firm noted.
For more new products and services, please visit the New Products page on our website.